Prof Jianjun Wang was invited to attend Tigermed’s ASCO Pre-Event Webinar as a Speaker to present Qurgen’s breakthrough cell converting cancer therapy and the recent progress of its Phase I clinical trial.
Fuent (Qurgen’s China subsidiary) has initiated its Phase I clinical trial in China following IND approval from Center for Drug Evaluation (CDE) The study is being conducted at the following clinical sites.
